Brefeldin A Delivery Nanomicelles in Hepatocellular Carcinoma Therapy: Characterization, Cytotoxic Evaluation In Vitro, and Antitumor Efficiency In Vivo.
Brefeldin A Delivery Nanomicelles in Hepatocellular Carcinoma Therapy: Characterization, Cytotoxic Evaluation In Vitro, and Antitumor Efficiency In Vivo.
复制标题
DOI：
10.1016/j.phrs.2021.105800
复制
发表时间：
2021-08
影响因子：
9.3
通讯作者：
Jinman Zhang;Yao-Yao Jiang-Yao;Qunfa Huang;Xuxiu Lu;Guan-Hai Wang;C. Shao;Ming Liu
中科院分区：
文献类型：
--
作者：
Jinman Zhang;Yao-Yao Jiang-Yao;Qunfa Huang;Xuxiu Lu;Guan-Hai Wang;C. Shao;Ming Liu
Hepatocellular carcinoma (HCC) is one of the major cancers with high mortality rate. Traditional drugs used in clinic are usually limited by the drug resistance and side effect and novel agents are still needed. Macrolide brefeldin A (BFA) is a well-known lead compound in cancer chemotherapy, however, with poor solubility and instability. In this study, to overcome these disadvantages, BFA was encapsulated in mixed nanomicelles based on TPGS and F127 copolymers (M-BFA). M-BFA was conferred high solubility, colloidal stability, and capability of sustained release of intact BFA.In vitro,M-BFA markedly inhibited the proliferation, induced G0/G1 phase arrest, and caspase-dependent apoptosis in human liver carcinoma HepG2 cells. Moreover, M-BFA also induced autophagic cell deathviaAkt/mTOR and ERK pathways. In HepG2 tumor-bearing xenograft mice, indocyanine green (ICG) as a fluorescent probe loaded in M-BFA distributed to the tumor tissue rapidly, prolonged the blood circulation, and improved the tumor accumulation capacity. More importantly, M-BFA (10 mg/kg) dramatically delayed the tumor progression and induced extensive necrosis of the tumor tissues. Taken together, the present work suggests that M-BFA has promising potential in HCC therapy.
